After releasing disappointing phase 3 data early last year and receiving a FDA rejection in August, shares of Portola Pharmaceuticals Portola Pharmaceuticals’ most advanced drugs in development are the factor Xa anticoagulant betrixaban and the factor Xa reversal agent AndexXa. In March, management reported betrixaban phase 3 trial data that left investors questioning the drug’s future.